SCHEMBL23780415

SCHEMBL23780415

CC(Nc1cc(Cl)ncn1)c1ccc(C(=N)NO)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRCP P42785 7/20 0.43
HTR7 P34969 3/20 0.38
JAK2 O60674 1/20 0.36
JAK3 P52333 1/20 0.36
HDAC8 Q9BY41 3/20 0.36
NPC1 O15118 1/20 0.35
HDAC3 O15379 2/20 0.34
KDR P35968 2/20 0.34
HDAC4 P56524 2/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC7 Q8WUI4 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC10 Q969S8 2/20 0.34
HDAC11 Q96DB2 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
HDAC9 Q9UKV0 2/20 0.34
HDAC5 Q9UQL6 2/20 0.34
ERBB2 P04626 1/20 0.34
EGFR P00533 1/20 0.34
CAMK2D Q13557 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23780468 0.81 PRCP (0.45) PRCPHTR7JAK2JAK3NPC1
SCHEMBL20575148 0.78 HTR7 (0.53) PRCPHTR7JAK2JAK3EGFR
SCHEMBL20575147 0.78 HTR7 (0.53) PRCPHTR7JAK2JAK3EGFR
SCHEMBL4375461 0.78 HTR7 (0.58) PRCPHTR7JAK2JAK3EGFR
SCHEMBL21593091 0.78 HTR7 (0.58) PRCPHTR7JAK2JAK3EGFR
SCHEMBL4375466 0.78 HTR7 (0.58) PRCPHTR7JAK2JAK3EGFR
SCHEMBL23291891 0.75 EGFR (0.45) PRCPHTR7JAK2JAK3EGFR
SCHEMBL23291971 0.74 HDAC3 (0.41) JAK2JAK3NPC1HDAC3HDAC1
SCHEMBL23780410 0.74 HDAC3 (0.41) JAK2JAK3NPC1HDAC3HDAC1
SCHEMBL20575173 0.72 PRCP (0.42) PRCPHTR7JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 PRCP 3219/4885HTR7 4221/4885JAK2 2656/4885
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 PRCP 3219/4885HTR7 4221/4885JAK2 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.